You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
Along with the downgrade, the investment bank also lowered its December 2021 price target for Illumina from $390 to $280.
The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
A Lund University-led team developed two methylation risk scores to predict which patients would or would not respond to treatment and experience side effects.
Methylation profiles of more than 23,000 individuals uncovered thousands of epivariations, including some affecting Mendelian disease genes.
Using transcriptomic, metabolomic, metagenomic, and other data types, a team identified purine metabolism as a potential target for intervention.
In PLOS this week: computational tool to uncover selection within populations, sequencing-based analysis of canine lymphoma, and more.
Researchers used the methylCIBERSORT algorithm to determine the makeup of the tumor immune microenvironment of about 6,000 pediatric central nervous system tumors.
The method, called jagged end analysis by sequencing and developed by a team in Hong Kong, relies on DNA end repair with methylated or unmethylated cytosine.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.